Navigo Proteins GmbH

Protein Drug Conjugates

Several of the Navigo-created, ready-to-go Affilin® molecules against solid tumor targets are currently developed as protein-drug conjugates (PDCs), by combining them to a half-life extending module and an engineered toxin-carrying moiety.

Compared to notoriously difficult-to-produce and inhomogeneous Antibody-Drug Conjugates (ADCs), Affilin®-based PDCs have clear advantages. They are easily assembled from a specificity-conferring Affilin®, a half-life extending module and a toxin-carrying moiety. Each of those modules can separately be optimized for its particular task and together they can be flexibly assembled into final drug candidates.

Affilin®-based PDCs can be single chain molecules, with engineered targeted carrier domains for specific drug conjugation sites and thus have a distinct Affilin®-drug ratio for minimal adverse effects. ADC manufacturability issues are greatly simplified by single chain Affilin®-drug conjugate expression in E. coli.